Financials in USD. Standardized financial statements.
A compact view of how Sonoma Pharmaceuticals, Inc. turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $14.29M | $12.73M | $13.27M | $12.63M | $18.63M | $17.93M | $18.97M | $16.66M | $12.82M | $9.37M |
| Revenue Growth? | +12.2% | -4.0% | +5.1% | -32.2% | +3.9% | -5.5% | +13.9% | +29.9% | +36.9% | 0.0% |
| Cost of Revenue? | $8.82M | $7.99M | $8.79M | $8.63M | $12.07M | $9.81M | $10.09M | $9.35M | $7.16M | $6.72M |
| Gross Profit? | $5.46M | $4.75M | $4.48M | $3.99M | $6.56M | $8.12M | $8.88M | $7.31M | $5.67M | $2.65M |
| Gross Margin? | +38.2% | +37.3% | +33.7% | +31.6% | +35.2% | +45.3% | +46.8% | +43.9% | +44.2% | +28.3% |
| Operating Expenses? | $9.18M | $9.45M | $9.05M | $9.88M | $10.01M | $15.51M | $20.14M | $21.50M | $18.64M | $17.36M |
| Operating Income? | -$3.71M | -$4.70M | -$4.57M | -$5.89M | -$3.45M | -$7.39M | -$11.26M | -$14.19M | -$12.97M | -$14.71M |
| EBITDA? | -$3.57M | -$4.53M | -$4.45M | -$5.70M | -$3.22M | -$3.22M | -$10.85M | -$13.75M | -$12.69M | -$14.48M |
| Income Before Tax | -$2.91M | -$5.03M | -$5.18M | -$5.42M | -$3.90M | -$3.54M | -$11.34M | -$14.28M | -$12.94M | -$14.72M |
| Income Tax Expense | $550,000 | -$196,000 | -$33,000 | -$332,000 | $713,000 | $29,000 | $458,000 | $50,000 | -$4.27M | $0 |
| Net Income? | -$3.46M | -$4.83M | -$5.15M | -$5.09M | -$3.95M | -$3.31M | -$11.80M | -$14.33M | $9.27M | -$10.16M |
| EPS? | $-2.79 | $-5.32 | $-15.18 | $-19.17 | $-23.65 | $-22.40 | $-127.68 | $-284.66 | $-221.70 | $-117.86 |
| Diluted EPS? | $-2.79 | $-5.32 | $-15.18 | $-19.17 | $-23.65 | $-22.40 | $-127.68 | $-284.66 | $-221.70 | $-117.81 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality